On April 9, 2026 Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, reported that it will have multiple oral and poster presentations at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting being held April 17-22, 2026, in San Diego, California. New preclinical data for Selective SMARCA2 inhibitor FHD-909 will be featured as part of an oral presentation and preclinical data for Selective CBP, Selective EP300, and Selective ARID1B degrader programs will be featured as poster presentations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"FHD-909 is advancing in the clinic in collaboration with Lilly as the first potential selective SMARCA2 inhibitor for the treatment of SMARCA4-mutant cancers. We are excited to present new, compelling preclinical data further supporting potential expansion opportunities in combination with an anti-PD-1 antibody, as part of Dr. Bellon’s oral presentation at this year’s AACR (Free AACR Whitepaper)," said Adrian Gottschalk, President, and Chief Executive Officer of Foghorn. "Poster presentations will also highlight additional preclinical data characterizing our wholly owned Selective CBP, Selective EP300, and Selective ARID1B degrader programs. Collectively, these data underscore the differentiated profiles of our pipeline programs which may translate to improved therapeutic outcomes for difficult to treat cancers with significant unmet need."

Oral Presentation Details

Title: Targeting chromatin regulatory proteins in hematologic malignancies
Town Meeting: Chemistry, Hematologic Malignancies – From Molecules to Medicine – Driving Breakthroughs in Blood Cancer Treatment: A CICR-HMWG Town Hall
Session Date/Time: Monday, April 20, 6:30 p.m. – 8:30 p.m. PDT
Presenter: Gromek Smolen, VP, Biology, Foghorn Therapeutics

Title: Leveraging paralog relationships for targeting chromatin modulators in cancer: ARID1B and SMARCA2 (FHD-909)
Session: Molecular/Cellular Biology and Genetics, Chemistry, Drug Development – Synthetic Lethality in Oncology: Progress Made, Pitfalls Encountered, and the Path Forward
Session Date/Time: Tuesday, April 21, 10:15 a.m. – 11:45 a.m. PDT
Presenter: Steven Bellon, Chief Scientific Officer, Foghorn Therapeutics

Title: Towards new cancer medicines with degraders of chromatin regulatory proteins
Session: Chemistry, Drug Development, Experimental and Molecular Therapeutics – Induced Proximity Pharmacology: Degraders and Beyond
Session Date/Time: Wednesday, April 22, 10:15 a.m. – 11:45 a.m. PDT
Presenter: Danette Daniels, VP, Degrader Platform, Foghorn Therapeutics

Poster Presentation Details

Title: Preclinical evaluation of selective and potent EP300 degraders demonstrates robust antitumor activity and favorable tolerability in hematologic malignancies
Session: Experimental and Molecular Therapeutics – Quantitative Pharmacology and Translational Modeling
Poster Number: 1828 / 16
Session Date/Time: Monday, April 20, 9:00 a.m. – 12:00 p.m. PDT
Presenter: Meiyun Lin, Senior Scientist, Pharmacology, Foghorn Therapeutics
Abstract: Click here

Title: Leveraging selective degradation of CBP and EP300 for potent anti-cancer activity
Session: Chemistry – Targeted Protein Degradation and Induced Proximity
Poster Number: 5163 / 13
Session Date/Time: Tuesday, April 21, 9:00 a.m. – 12:00 p.m. PDT
Presenter: Karolina Mizeracka, Principal Scientist, Cell Biology, Foghorn Therapeutics
Abstract: Click here

Title: Identification of first-in-class selective ARID1B degraders
Session: Experimental and Molecular Therapeutics – Proximity-Induced Drug Discovery 2
Poster Number: 5792 / 19
Session Date/Time: Tuesday, April 21, 2:00 p.m. – 5:00 p.m. PDT
Presenter: Madeleine Henley, Senior Scientist, Foghorn Therapeutics
Abstract: Click here

Title: Preclinical characterization of FHT-171, a first-in-class degrader targeting CREB-binding protein (CBP) in CBP-dependent solid tumors
Session: Experimental and Molecular Therapeutics – Epigenetic Modulators 2
Poster Number: 7075 / 22
Session Date/Time: Wednesday, April 22 9:00 a.m. – 12:00 p.m. PDT
Presenter: Darshan Sappal, Director, Biology, Foghorn Therapeutics
Abstract: Click here

Dr. Bellon’s presentation and the posters will be accessible under the Science section of the Company’s website.

(Press release, Foghorn Therapeutics, APR 9, 2026, View Source [SID1234664291])

On April 9, 2026 Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies, reported the cumulative closing of a pre-IPO financing round in excess of $110 million. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund. The syndicate included an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Proceeds will be strategically allocated to accelerate Oricell’s global expansion and clinical development, while strengthening its technological capabilities and paving the way to capital market milestones.

As a frontrunner in cell therapy, OriCell is focused on engineering CAR-Ts with global clinical impact, having already secured confirmatory proof-of-concept (POC) data across multiple pipelines. By leveraging its proprietary triad: the OriAb antibody screening and engineering platform, the OriArmoring functional enhancement platform, and the OnGo (Fast) rapid CMC manufacturing expertise, the company has built a differentiated portfolio that positions it at the vanguard of the global CAR-T race.

OriCell’s lead asset, Ori-C101, is a GPC3-targeted autologous CAR-T therapy for advanced hepatocellular carcinoma (HCC). Having successfully navigated investigator-initiated trials (IIT) and a registrational Phase 1 study, the program is now gearing up for pivotal trials. Clinical readouts have demonstrated a best-in-class efficacy and safety profile, with data highlighted at major forums including the ASCO (Free ASCO Whitepaper) Annual Meeting. With these promising results, Ori-C101 is positioned to become the first-in-class CAR-T therapy approved globally for HCC.

Beyond its lead asset, Oricell is aggressively advancing a diverse portfolio of next-generation modalities, including secreted, rapid-production, and in vivo CAR-T programs.

Dr. Huanfeng Yang, Chairman and CEO of Oricell Therapeutics, stated: "This financing is a testament to the global potential of our science and the dedication of our team. As we approach key inflection points in our clinical programs, our priority is clear: expedite the global development of our core assets and deepening our research into revolutionary technologies, including in vivo CAR-T and solid tumor CAR-T. We are committed to delivering transformative therapies that offer real hope to cancer patients worldwide, positioning Oricell as a dominant force in the global immunotherapy arena."

Mr. Shan Fu, Managing Partner at Vivo Capital, commented: "While cell therapy is undoubtedly the future of oncology, solid tumors remain the industry’s toughest nut to crack. Oricell distinguishes itself not just through best-in-class clinical data for its GPC3 CAR-T, but also through a pragmatic and visionary roadmap for next-generation modalities like in vivo CAR-T. We have high conviction in their integrated ‘Platform and Pipeline’ strategy and believe they are poised to set the new standard of care in the field. Vivo Capital is eager to deploy our global network to accelerate Oricell’s expansion into international markets."

Mr. William Hu, Managing Partner at Qiming Venture Partners, stated: "As an early investor that has stood with Oricell since the Pre-A round, we have witnessed every milestone of its journey—from technological exploration to pipeline realization, and from local innovation to global expansion. We look forward to Oricell leveraging breakthrough cell therapy solutions and stronger clinical data to define the next generation of cancer care, bringing hope to patients worldwide."

(Press release, OriCell Therapeutics, APR 9, 2026, View Source [SID1234664276])

On April 9, 2026 Boehringer Ingelheim reported a clinical trial collaboration with BioNTech to evaluate a novel immuno‑oncology combination in extensive‑stage small cell lung cancer (ES-SCLC), one of the most aggressive and underserved forms of cancer. Under the agreement, BioNTech will supply pumitamig (BNT327/BMS‑986545), a PD‑L1/VEGF‑A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb, and Boehringer Ingelheim will be the regulatory sponsor of the Phase Ib/II study. The aim is to assess safety, tolerability and early clinical activity of obrixtamig (BI 764532), Boehringer Ingelheim’s investigational DLL3/CD3 T‑cell engager, in combination with pumitamig.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SCLC is the most aggressive subtype of lung cancer and represents around 15–20% of all lung cancer cases. It progresses rapidly, metastasizes early and almost always recurs within a year after initial treatment. While the addition of immune checkpoint inhibitors to chemotherapy has led to improved survival outcomes for patients with extensive-stage disease, most patients progress within months after treatment, and the prognosis remains poor. The collaboration combines two complementary immunotherapeutic mechanisms to explore a potential new path to enhance and sustain antitumor immunity. Obrixtamig redirects T-cells to kill DLL3 expressing tumor cells, while pumitamig aims to restore T-cells’ ability to recognize and destroy tumor cells while cutting off the blood and oxygen supply that feeds the tumor with the intention of preventing it from growing and proliferating.

"By uniting T‑cell redirection against DLL3 with PD-L1 and VEGF pathway modulation, we aim to address two central barriers in SCLC – immune evasion and an immunosuppressive, pro‑angiogenic microenvironment," said Itziar Canamasas, Global Head of Oncology at Boehringer Ingelheim. "We are committed to advancing combinations that could deliver more durable benefit for people living with ES‑SCLC."

Obrixtamig is Boehringer Ingelheim’s investigational bispecific DLL3/CD3 T‑cell engager, designed to direct immune cells to attack DLL3‑expressing cancer cells, a hallmark of small cell lung cancer and other neuroendocrine carcinomas. In the global Phase I first‑line ES‑SCLC study DAREON‑8, in combination with chemotherapy and atezolizumab, obrixtamig achieved a 68% confirmed objective response rate, 89% disease control rate, and a 9‑month progression‑free survival rate of 52%, with a favorable safety profile1. Obrixtamig is being evaluated across multiple global studies and is advancing into a global Phase III trial (DAREON‑Lung‑1, NCT07472517). It has received FDA Fast Track and Orphan Drug Designations, as well as Orphan Drug status from the European Commission for neuroendocrine carcinomas.

Pumitamig is an investigational PD‑L1/VEGF‑A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb that combines two complementary, validated mechanisms in one single molecule – immune checkpoint inhibition and anti-angiogenesis. In a global Phase II first‑line ES‑SCLC study in combination with chemotherapy, pumitamig demonstrated a 76.3% confirmed objective response rate, 100% disease control rate, and median progression-free survival of 6.8 months, with a manageable safety profile2. The program has advanced into a global Phase III trial (ROSETTA LUNG‑01, NCT06712355) and received FDA Orphan Drug Designation in 2025 for the treatment of SCLC.

Under the terms of the agreement, BioNTech will supply pumitamig and Boehringer Ingelheim will be the regulatory sponsor of the study. Both companies retain full rights to their respective assets, and the agreement is mutually non-exclusive. The trial will begin dosing patients in the second half of 2026.

(Press release, Boehringer Ingelheim, APR 9, 2026, View Source [SID1234664292])

On April 9, 2026 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported that Dr. Amit Kumar, Anixa’s Chairman and CEO, will participate in the upcoming RedChip Biotech Resurgence: Platforms and Pipelines of Today’s Innovators virtual investor conference on April 16, 2026, at 3:30 pm ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will cover several topics, including an overview of the Company and its business model, the Company’s breast cancer vaccine meeting primary endpoints and generating protocol-defined immune responses in 74% of participants in its Phase 1 clinical trial, and the Company’s ovarian cancer CAR-T therapy, lira-cel, exhibiting positive survival data in its ongoing Phase 1 clinical trial.

RedChip’s virtual investor conference brings investors direct access to publicly traded companies advancing the future of healthcare across biopharma, medtech, diagnostics, and digital health. Throughout this full-day virtual event, company executives will present their business models, pipeline strategies, clinical and commercial milestones, and competitive positioning within an evolving healthcare landscape. Each session will include a live Q&A, giving investors the opportunity to engage directly with leadership teams.

Registration to attend this virtual investor conference may be completed at: Event Registration.

(Press release, Anixa Biosciences, APR 9, 2026, View Source [SID1234664261])

On April 9, 2026 Alpheus Medical, Inc., a private, clinical-stage biotechnology company, reported the initiation of its Phase 2b randomized controlled trial in newly diagnosed glioblastoma (nGBM) with 10 patients enrolled to date and additional clinical sites continuing to come online.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Glioblastoma is a highly infiltrative brain tumor in which cancer cells extend beyond the visible tumor margins and spread throughout the brain hemisphere, limiting the effectiveness of surgery and localized therapies.

To address this challenge, the Alpheus study is evaluating an investigational therapy based on Porphyrin Metabolite Activation (PoMA), an approach previously described in the literature as Sonodynamic Therapy (SDT). This drug-centered approach leverages a molecule that preferentially accumulates in tumor cells, followed by activation using low-intensity ultrasound to enable localized pharmacologic effects. The treatment is designed to act within tumor cells throughout the affected hemisphere.

"Glioblastoma patients have few effective treatment options and poor long-term outcomes, highlighting the urgent need for innovation," said David Reardon, MD, Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute, and Principal Investigator of the study. "Alpheus’ approach is designed to address the diffuse nature of the disease by enabling treatment across the affected hemisphere. We look forward to generating data to understand its potential role in patient care."

"The Phase 2b trial marks an important step forward in bringing our new therapeutic approach to patients with glioblastoma," said Vijay Agarwal, MD, FAANS, FCNS, Chief Executive Officer of Alpheus Medical. "We believe our drug-centered approach has the potential to address the diffuse nature of the disease in ways that localized treatment cannot. With strong early enrollment, we are focused on generating the randomized clinical data to advance this therapy."

About the Therapy and Trial
Alpheus Medical is developing a novel therapeutic approach based on Porphyrin Metabolite Activation (PoMA), a drug-centered strategy that leverages a molecule that preferentially accumulates in tumor cells, followed by activation using low-intensity, diffuse ultrasound designed to enable treatment across the affected hemisphere, achieving localized pharmacologic effects. Previously described in clinical literature as SDT, this non-invasive approach is intended to activate the molecule directly within tumor cells while minimizing systemic exposure.

The company’s Phase 2b study (NCT07225621) is a multi-center, randomized trial expected to enroll more than 100 newly diagnosed high-grade glioma patients at up to 15 U.S and European sites. Eligible patients have undergone resection and standard radiochemotherapy. The study compares standard of care alone to standard of care plus investigational therapy. The primary endpoint is progression-free survival (PFS) with key secondary endpoints including overall survival (OS), safety, and tolerability.

For patients and caregivers seeking more information about the study and enrolling sites, visit www.BrainCancerTrial.com.

(Press release, Alpheus Medical, APR 9, 2026, View Source [SID1234664277])